Powerbrands lift GSK's Consumer Healthcare

31 October 2016 - Deborah Wilkes

Archived

GlaxoSmithKline said its powerbrands – especially Sensodyne, Voltaren and Otrivin – had helped drive worldwide sales at its Consumer Healthcare business up by 5% at constant exchange rates to £1.87 billion (US$2.33 billion) in the third quarter of 2016.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: